Login Register Cart 0
Generic placeholder image

Current Diabetes Reviews

Editor-in-Chief

ISSN (Print): 1573-3998
ISSN (Online): 1875-6417

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Review Article

Pharmacological Management of Diabetes for Reducing Glucose Levels and Cardiovascular Disease Risk: What Evidence in South Asians?

Author(s): Nazim Ghouri, Hareem Javed and Naveed Sattar*

Volume 17, Issue 9, 2021

Published on: 28 December, 2020

Article ID: e122820189511 Pages: 9

DOI: 10.2174/1573399817666201228120725

Price: $65

Abstract

Introduction: South Asians experience more type 2 diabetes, which is earlier in onset and with more rapid glycaemic deterioration, although average body mass indices are lower than in whites. Cardiovascular outcomes from diabetes drug trials are now reported as standard, with data from newer therapies influencing patient management. However, less is known of the effect of such therapies in South Asians. The aim of this narrative review was to extract, wherever possible, the glucose-lowering efficacy and cardiovascular and renal outcome data for these therapies in South Asians.

Discussion: Despite the higher prevalence and global burden of type 2 diabetes and adverse outcomes in South Asians, they remain underrepresented in global trials. Even when recruited, the current method of classifying ethnicity does not commonly allow South Asian data to be extracted and reported separately from all Asians. Interrogation of available trial data suggests broadly comparable effects on glycaemia and weight in Asians to other ethnicities with use of glucagon-like peptide 1 receptor agonists (GLP-1 RAs), but a potentially early, albeit marginally, greater glycaemia benefit with Dipeptidyl peptidase-4 inhibitors (DPP4is) which may not be sustained. Furthermore, there appears a potentially greater glycaemia benefit with use of sodium-glucose transport protein 2 inhibitors (SGLT2is) in Asians compared to whites. Whether such findings are true in all Asians subgroups requires further direct study. For cardiovascular outcomes, available data suggest at least comparable and potentially greater outcome benefits in Asians; point estimates were more favourable for Asians in the vast majority of GLP-1 RAs and SGLT2is outcome trials. It was, however, impossible to determine whether the effects were similar across all Asian subgroups.

Conclusion: We conclude that trialists should be encouraged to record ethnicity with better granularity to allow differing ethnic groups data to be better interrogated. In the meantime, doctors should, where possible, confidently follow newer guidelines for the use of newer glucose lowering agents for treating glycaemia and for the prevention of cardiovascular and cardiorenal complications in South Asian people with type 2 diabetes.

Keywords: South Asian, type 2 diabetes, CVD, treatment, efficacy, cardiovascular risk, Indian.

[1]
Sattar N, Rawshani A, Franzén S, et al. Age at diagnosis of type 2 diabetes mellitus and associations with cardiovascular and mortality risks. Circulation 2019; 139(19): 2228-37.
[http://dx.doi.org/10.1161/CIRCULATIONAHA.118.037885] [PMID: 30955347]
[2]
Herrington WG, Alegre-Díaz J, Wade R, et al. Effect of diabetes duration and glycaemic control on 14-year cause-specific mortality in Mexican adults: a blood-based prospective cohort study. Lancet Diabetes Endocrinol 2018; 6(6): 455-63.
[http://dx.doi.org/10.1016/S2213-8587(18)30050-0] [PMID: 29567074]
[3]
Misra A, Sattar N, Tandon N, et al. Clinical management of type 2 diabetes in south Asia. Lancet Diabetes Endocrinol 2018; 6(12): 979-91.
[http://dx.doi.org/10.1016/S2213-8587(18)30199-2] [PMID: 30287103]
[4]
Zoungas S, Arima H, Gerstein HC, et al. Collaborators on Trials of Lowering Glucose (CONTROL) group. Effects of intensive glucose control on microvascular outcomes in patients with type 2 diabetes: a meta-analysis of individual participant data from randomised controlled trials. Lancet Diabetes Endocrinol 2017; 5(6): 431-7.
[http://dx.doi.org/10.1016/S2213-8587(17)30104-3] [PMID: 28365411]
[5]
Ray KK, Seshasai SRK, Wijesuriya S, et al. Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials. Lancet 2009; 373(9677): 1765-72.
[http://dx.doi.org/10.1016/S0140-6736(09)60697-8] [PMID: 19465231]
[6]
Kristensen SL, Rørth R, Jhund PS, et al. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet Diabetes Endocrinol 2019; 7(10): 776-85.
[http://dx.doi.org/10.1016/S2213-8587(19)30249-9] [PMID: 31422062]
[7]
Woo VC. Cardiovascular effects of sodium-glucose cotransporter-2 inhibitors in adults with type 2 diabetes. Can J Diabetes 2020; 44(1): 61-7.
[http://dx.doi.org/10.1016/j.jcjd.2019.09.004] [PMID: 31839265]
[8]
Buse JB, Wexler DJ, Tsapas A, et al. 2019 update to: Management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2020; 43(2): 487-93.
[http://dx.doi.org/10.2337/dci19-0066] [PMID: 31857443]
[9]
Cosentino F, Grant PJ, Aboyans V, et al. ESC Scientific Document Group. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J 2020; 41(2): 255-323.
[http://dx.doi.org/10.1093/eurheartj/ehz486] [PMID: 31497854]
[10]
Narayan KMV, Kanaya AM. Why are South Asians prone to type 2 diabetes? A hypothesis based on underexplored pathways. Diabetologia 2020; 63(6): 1103-9.
[http://dx.doi.org/10.1007/s00125-020-05132-5] [PMID: 32236731]
[11]
Sattar N, Gill JMR. Type 2 diabetes in migrant south Asians: mechanisms, mitigation, and management. Lancet Diabetes Endocrinol 2015; 3(12): 1004-16.
[http://dx.doi.org/10.1016/S2213-8587(15)00326-5] [PMID: 26489808]
[12]
Wright AK, Welsh P, Gill JMR, et al. Age-, sex- and ethnicity-related differences in body weight, blood pressure, HbA1c and lipid levels at the diagnosis of type 2 diabetes relative to people without diabetes. Diabetologia 2020; 63(8): 1542-53.
[http://dx.doi.org/10.1007/s00125-020-05169-6] [PMID: 32435821]
[13]
Davies MJ, D’Alessio DA, Fradkin J, et al. Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2018; 41(12): 2669-701.
[http://dx.doi.org/10.2337/dci18-0033] [PMID: 30291106]
[14]
Wu S, Chai S, Yang J, et al. Gastrointestinal adverse events of dipeptidyl peptidase 4 inhibitors in type 2 diabetes: a systematic review and network meta-analysis. Clin Ther 2017; 39(9): 1780-1789.e33.
[http://dx.doi.org/10.1016/j.clinthera.2017.07.036] [PMID: 28827024]
[15]
Htike ZZ, Zaccardi F, Papamargaritis D, Webb DR, Khunti K, Davies MJ. Efficacy and safety of glucagon-like peptide-1 receptor agonists in type 2 diabetes: A systematic review and mixed-treatment comparison analysis. Diabetes Obes Metab 2017; 19(4): 524-36.
[http://dx.doi.org/10.1111/dom.12849] [PMID: 27981757]
[16]
Andreadis P, Karagiannis T, Malandris K, et al. Semaglutide for type 2 diabetes mellitus: A systematic review and meta-analysis. Diabetes Obes Metab 2018; 20(9): 2255-63.
[http://dx.doi.org/10.1111/dom.13361] [PMID: 29756388]
[17]
Vasilakou D, Karagiannis T, Athanasiadou E, et al. Sodium-glucose cotransporter 2 inhibitors for type 2 diabetes: a systematic review and meta-analysis. Ann Intern Med 2013; 159(4): 262-74.
[http://dx.doi.org/10.7326/0003-4819-159-4-201308200-00007] [PMID: 24026259]
[18]
Lee PC, Ganguly S, Goh SY. Weight loss associated with sodium-glucose cotransporter-2 inhibition: a review of evidence and underlying mechanisms. Obes Rev 2018; 19(12): 1630-41.
[http://dx.doi.org/10.1111/obr.12755] [PMID: 30253050]
[19]
Esposito K, Chiodini P, Maiorino MI, Bellastella G, Capuano A, Giugliano D. Glycaemic durability with dipeptidyl peptidase-4 inhibitors in type 2 diabetes: a systematic review and meta-analysis of long-term randomised controlled trials. BMJ Open 2014; 4(6): e005442.
[http://dx.doi.org/10.1136/bmjopen-2014-005442] [PMID: 24916090]
[20]
Aroda VR, Henry RR, Han J, et al. Efficacy of GLP-1 receptor agonists and DPP4is: meta-analysis and systematic review. Clin Ther 2012; 34(6): 1247-1258.e22.
[http://dx.doi.org/10.1016/j.clinthera.2012.04.013] [PMID: 22608780]
[21]
Sorli C, Harashima SI, Tsoukas GM, et al. Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial. Lancet Diabetes Endocrinol 2017; 5(4): 251-60.
[http://dx.doi.org/10.1016/S2213-8587(17)30013-X] [PMID: 28110911]
[22]
Buse JB, Peters A, Russell-Jones D, et al. Is insulin the most effective injectable antihyperglycaemic therapy? Diabetes Obes Metab 2015; 17(2): 145-51.
[http://dx.doi.org/10.1111/dom.12402] [PMID: 25323312]
[23]
Zinman B, Wanner C, Lachin JM, et al. EMPA-REG OUTCOME Investigators. empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 2015; 373(22): 2117-28.
[http://dx.doi.org/10.1056/NEJMoa1504720] [PMID: 26378978]
[24]
Neal B, Perkovic V, Mahaffey KW, et al. CANVAS Program Collaborative Group. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med 2017; 377(7): 644-57.
[http://dx.doi.org/10.1056/NEJMoa1611925] [PMID: 28605608]
[25]
Storgaard H, Gluud LL, Bennett C, et al. Benefits and harms of Sodium-Glucose co-Transporter 2 inhibitors in patients with type 2 diabetes: A systematic review and Meta-Analysis. PLoS One 2016; 11(11): e0166125.
[http://dx.doi.org/10.1371/journal.pone.0166125] [PMID: 27835680]
[26]
Li J, Gong Y, Li C, Lu Y, Liu Y, Shao Y. Long-term efficacy and safety of sodium-glucose cotransporter-2 inhibitors as add-on to metformin treatment in the management of type 2 diabetes mellitus. Med (United States) 2017; 96(27): e7201.
[http://dx.doi.org/10.1097/MD.0000000000007201]
[27]
Wilding J, Bailey C, Rigney U, Blak B, Kok M, Emmas C. Dapagliflozin therapy for type 2 diabetes in primary care: Changes in HbA1c, weight and blood pressure over 2 years follow-up. Prim Care Diabetes 2017; 11(5): 437-44.
[http://dx.doi.org/10.1016/j.pcd.2017.04.004] [PMID: 28583425]
[28]
McGurnaghan SJ, Brierley L, Caparrotta TM, et al. Scottish Diabetes Research Network Epidemiology Group. The effect of dapagliflozin on glycaemic control and other cardiovascular disease risk factors in type 2 diabetes mellitus: a real-world observational study. Diabetologia 2019; 62(4): 621-32.
[http://dx.doi.org/10.1007/s00125-018-4806-9] [PMID: 30631892]
[29]
Tiwaskar M. Insights (insites) on DPP 4 inhibitors (gliptins) for diabetes management in India. J Assoc Physicians India 2019; 67(10): 11-2.
[PMID: 31571444]
[30]
Mohan V, Yang W, Son HY, et al. Efficacy and safety of sitagliptin in the treatment of patients with type 2 diabetes in China, India, and Korea. Diabetes Res Clin Pract 2009; 83(1): 106-16.
[http://dx.doi.org/10.1016/j.diabres.2008.10.009] [PMID: 19097665]
[31]
Gan S, Dawed AY, Donnelly LA, et al. Efficacy of modern diabetes treatments DPP-4i, sglt-2i, and GLP-1 RAs in white and asian patients with diabetes: A systematic review and metaanalysis of randomized controlled trials. Diabetes Care 2020; 43: 1948-57.
[http://dx.doi.org/10.2337/dc19-2419]
[32]
Kozlovski P, Fonseca M, Mohan V, et al. Effect of race and ethnicity on vildagliptin efficacy: A pooled analysis of phase II and III studies. Diabetes Obes Metab 2017; 19(3): 429-35.
[http://dx.doi.org/10.1111/dom.12844] [PMID: 27943546]
[33]
Sheu WHH, Brunell SC, Blase E. Efficacy and tolerability of exenatide twice daily and exenatide once weekly in Asian versus White patients with type 2 diabetes mellitus: A pooled analysis. Diabetes Res Clin Pract 2016; 114: 160-72.
[http://dx.doi.org/10.1016/j.diabres.2015.12.004] [PMID: 26827116]
[34]
Yang L, Zhang L, He H, Zhang M, An Z. Efficacy and safety of sodium-glucose cotransporter 2 inhibitors in east asians with type 2 diabetes: a systematic review and meta-analysis. Diabetes Ther 2019; 10(5): 1921-34.
[http://dx.doi.org/10.1007/s13300-019-0674-7] [PMID: 31376072]
[35]
Johnston R, Uthman O, Cummins E, et al. Canagliflozin, dapagliflozin and empagliflozin monotherapy for treating type 2 diabetes: systematic review and economic evaluation. Health Technol Assess 2017; 21(2): 1-218.
[http://dx.doi.org/10.3310/hta21020] [PMID: 28105986]
[36]
Ji L, Ma J, Li H, et al. Dapagliflozin as monotherapy in drug-naive Asian patients with type 2 diabetes mellitus: a randomized, blinded, prospective phase III study. Clin Ther 2014; 36(1): 84-100.
[http://dx.doi.org/10.1016/j.clinthera.2013.11.002] [PMID: 24378206]
[37]
El Masri D, Ghosh S, Jaber LA. Safety and efficacy of sodium-glucose cotransporter 2 (SGLT2) inhibitors in type 1 diabetes: A systematic review and meta-analysis. Diabetes Res Clin Pract 2018; 137: 83-92.
[http://dx.doi.org/10.1016/j.diabres.2018.01.004] [PMID: 29317332]
[38]
Hassanein M, Al-Arouj M, Hamdy O, et al. International Diabetes Federation (IDF), in collaboration with the Diabetes and Ramadan (DAR) international alliance. diabetes and ramadan: practical guidelines. Diabetes Res Clin Pract 2017; 126: 303-16.
[http://dx.doi.org/10.1016/j.diabres.2017.03.003] [PMID: 28347497]
[39]
Ahmed SH, Chowdhury TA, Hussain S, et al. Ramadan and diabetes: a narrative review and practice update. Diabetes Ther 2020; 11(11): 2477-520.
[http://dx.doi.org/10.1007/s13300-020-00886-y] [PMID: 32909192]
[40]
Cefalu WT, Kaul S, Gerstein HC, et al. Cardiovascular outcomes trials in type 2 diabetes: where do we go from here? reflections from a diabetes care editors’ expert forum. Diabetes Care 2018; 41(1): 14-31.
[http://dx.doi.org/10.2337/dci17-0057] [PMID: 29263194]
[41]
Type 2 Diabetes Mellitus: Evaluating the Safety of New Drugs for Improving Glycemic Control Guidance for Industry | FDA https://www.fda.gov/regulatory-information/search-fda-guidance-documents/type-2-diabetes-mellitus-evaluating-safety-new-drugs-improving-glycemic-control-guidance-industry
[42]
Laakso M. Cardiovascular disease in type 2 diabetes from population to man to mechanisms: the Kelly West Award Lecture 2008. Diabetes Care 2010; 33(2): 442-9.
[http://dx.doi.org/10.2337/dc09-0749] [PMID: 20103560]
[43]
Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007; 356(24): 2457-71.
[http://dx.doi.org/10.1056/NEJMoa072761] [PMID: 17517853]
[44]
Kieffer CM, Robertson AS. Impact of fda-required cardiovascular outcome trials on type 2 diabetes clinical study initiation from 2008 to 2017. Ther Innov Regul Sci 2019; 2168479019860122.
[http://dx.doi.org/10.1177/2168479019860122] [PMID: 31311308]
[45]
European Medicines Agency. Guideline on clinical investigation of medicinal products in the treatment or prevention of diabetes mellitus. Eur Med Agency 2012; 44: 1-28.
[46]
Scirica BM, Bhatt DL, Braunwald E, et al. SAVOR-TIMI 53 Steering Committee and Investigators. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med 2013; 369(14): 1317-26.
[http://dx.doi.org/10.1056/NEJMoa1307684] [PMID: 23992601]
[47]
Green JB, Bethel MA, Armstrong PW, et al. TECOS Study Group. Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. N Engl J Med 2015; 373(3): 232-42.
[http://dx.doi.org/10.1056/NEJMoa1501352] [PMID: 26052984]
[48]
White WB, Cannon CP, Heller SR, et al. EXAMINE Investigators. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med 2013; 369(14): 1327-35.
[http://dx.doi.org/10.1056/NEJMoa1305889] [PMID: 23992602]
[49]
Rosenstock J, Perkovic V, Johansen OE, et al. CARMELINA Investigators. Effect of linagliptin vs placebo on major cardiovascular events in adults with type 2 diabetes and high cardiovascular and renal risk: the carmelina randomized clinical trial. JAMA 2019; 321(1): 69-79.
[http://dx.doi.org/10.1001/jama.2018.18269] [PMID: 30418475]
[50]
Rosenstock J, Kahn SE, Johansen OE, et al. Effect of linagliptin vs glimepiride on major adverse cardiovascular outcomes in patients with type 2 diabetes: the carolina randomized clinical trial. JAMA - JAMA 2019; 322: 1155-66.
[http://dx.doi.org/10.1001/jama.2019.13772]
[51]
Marso SP, Daniels GH, Brown-Frandsen K, et al. LEADER Steering Committee; LEADER Trial Investigators. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med 2016; 375(4): 311-22.
[http://dx.doi.org/10.1056/NEJMoa1603827] [PMID: 27295427]
[52]
Marso SP, Bain SC, Consoli A, et al. SUSTAIN-6 Investigators. semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med 2016; 375(19): 1834-44.
[http://dx.doi.org/10.1056/NEJMoa1607141] [PMID: 27633186]
[53]
Hernandez AF, Green JB, Janmohamed S, et al. Harmony Outcomes committees and investigators. Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial. Lancet 2018; 392(10157): 1519-29.
[http://dx.doi.org/10.1016/S0140-6736(18)32261-X] [PMID: 30291013]
[54]
Gerstein HC, Colhoun HM, Dagenais GR, et al. REWIND Investigators. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet 2019; 394(10193): 121-30.
[http://dx.doi.org/10.1016/S0140-6736(19)31149-3] [PMID: 31189511]
[55]
Pfeffer MA, Claggett B, Diaz R, et al. ELIXA Investigators. Lixisenatide in patients with type 2 diabetes and acute coronary syndrome. N Engl J Med 2015; 373(23): 2247-57.
[http://dx.doi.org/10.1056/NEJMoa1509225] [PMID: 26630143]
[56]
Holman RR, Bethel MA, Mentz RJ, et al. EXSCEL Study Group. Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes. N Engl J Med 2017; 377(13): 1228-39.
[http://dx.doi.org/10.1056/NEJMoa1612917] [PMID: 28910237]
[57]
Husain M, Birkenfeld AL, Donsmark M, et al. PIONEER 6 Investigators. Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med 2019; 381(9): 841-51.
[http://dx.doi.org/10.1056/NEJMoa1901118] [PMID: 31185157]
[58]
Singh AK, Singh R. Cardiovascular outcomes with SGLT-2 inhibitors and GLP-1 receptor agonist in Asians with type 2 diabetes: A systematic review and meta-analysis of cardiovascular outcome trials. Diabetes Metab Syndr 2020; 14(4): 715-22.
[http://dx.doi.org/10.1016/j.dsx.2020.04.051] [PMID: 32470852]
[59]
Mahaffey KW, Jardine MJ, Bompoint S, et al. Canagliflozin and cardiovascular and renal outcomes in type 2 diabetes mellitus and chronic kidney disease in primary and secondary cardiovascular prevention groups. Circulation 2019; 140(9): 739-50.
[http://dx.doi.org/10.1161/CIRCULATIONAHA.119.042007] [PMID: 31291786]
[60]
Heerspink HJL, Stefánsson BV, Correa-Rotter R, et al. DAPA-CKD Trial committees and investigators. dapagliflozin in patients with chronic kidney disease. N Engl J Med 2020; 383(15): 1436-46.
[http://dx.doi.org/10.1056/NEJMoa2024816] [PMID: 32970396]
[61]
McMurray JJV, Solomon SD, Inzucchi SE, et al. DAPA-HF Trial Committees and Investigators. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med 2019; 381(21): 1995-2008.
[http://dx.doi.org/10.1056/NEJMoa1911303] [PMID: 31535829]
[62]
Packer M, Anker SD, Butler J, et al. EMPEROR-Reduced trial investigators. cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med 2020; 383(15): 1413-24.
[http://dx.doi.org/10.1056/NEJMoa2022190] [PMID: 32865377]
[63]
McMurray JJV, DeMets DL, Inzucchi SE, et al. DAPA-HF Committees and Investigators. The Dapagliflozin And Prevention of Adverse-outcomes in Heart Failure (DAPA-HF) trial: baseline characteristics. Eur J Heart Fail 2019; 21(11): 1402-11.
[http://dx.doi.org/10.1002/ejhf.1548] [PMID: 31309699]
[64]
Wiviott SD, Raz I, Bonaca MP, et al. DECLARE-TIMI 58 Investigators. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med 2019; 380(4): 347-57.
[http://dx.doi.org/10.1056/NEJMoa1812389] [PMID: 30415602]
[65]
Perkovic V, Jardine MJ, Neal B, et al. CREDENCE Trial investigators. canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med 2019; 380(24): 2295-306.
[http://dx.doi.org/10.1056/NEJMoa1811744] [PMID: 30990260]
[66]
Kaul S. Mitigating cardiovascular risk in type 2 diabeteswith antidiabetes drugs: A review of principal cardiovascular outcome results of EMPA-REG OUTCOME, LEADER, and SUSTAIN-6 trials. Diabetes Care 2017; 40(7): 821-31.
[http://dx.doi.org/10.2337/dc17-0291] [PMID: 28637887]
[67]
Cannon CP, Pratley R, Dagogo-Jack S, et al. VERTIS CV investigators. Cardiovascular outcomes with ertugliflozin in type 2 diabetes. N Engl J Med 2020; 383(15): 1425-35.
[http://dx.doi.org/10.1056/NEJMoa2004967] [PMID: 32966714]
[68]
Lee MMY, Ghouri N, McGuire DK, Rutter MK, Sattar N. Meta-analyses of results from randomized outcome trials comparing cardiovascular effects of SGLT2i and GLP-1RA in Asian vs. White patients with and without type 2 diabetes (IN press) Diabetes Care. 2021; 44(5): 1236-41.

Rights & Permissions Print Cite
Article Metrics
23
1
© 2024 Bentham Science Publishers | Privacy Policy